GlaxoSmithKline (GSK) has begun the sale of some of its consumer health brands ... Boutique investment bank Greenhill is to market the products to separate bidders, three anonymous sources ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GlaxoSmithKline has announced its second major deal this month, signing an agreement with Pfizer to combine its consumer health business ... largest over-the-counter products firm in the world ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GSK Consumer’s (GSK’s) Q2FY19 revenue, Ebitda and PAT growth of 14%, 35% and 43% y-o-y, respectively, surpassed estimates. This was the fourth consecutive quarter of strong volume spurt ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.